Is there utility in metronomic chemotherapy in adolescent and young adult patients with refractory sarcoma?  

I agree with Dr. @Michael Isakoff. In the absence of a standard second or beyond-line therapy in the sarcoma relapse setting, particularly one in which the outcome is expected to be especially poor, one must balance a number of factors in selecting a salvage regimen. One of the most important of the...

Unfortunately, there is a general lack of data to help answer this question. However, in a phase II study of pediatric patients (see below), there were some patients enrolled with bone sarcomas and only one had stable disease and no responses. On the other hand, oral cytoxan given daily (arguab...